Interventionelle, medikamentöse Studien
Titel
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Indikation
Multiples Myelom
Art der Studie
Therapiestudie, interventionell, Phase 3
Therapielinie
Zweitlinientherapie
Hauptprüfer am Zentrum (PI)
apl. Prof. med. Lutz P. Müller
Ansprechpartner
S. Edemir
Telefon: 0345/ 557 3170
Mail: sabine.edemir☉uk-halle.de
J. Ochsendorf
Telefon: 0345/ 557 2213
Titel
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Indikation
Multiples Myelom
Art der Studie
Therapiestudie, interventionell, Phase 3
Therapielinie
ab Zweitlinientherapie
Hauptprüfer am Zentrum (PI)
Dr. med. F. Brunner
Ansprechpartner
S. Edemir
Telefon: 0345/ 557 3170
Titel
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Indikation
Multiples Myelom
Art der Studie
Therapiestudie, interventionell, Phase 3
Therapielinie
Erstlinientherapie
Hauptprüfer am Zentrum (PI)
Dr. med. F. Brunner
Ansprechpartner
S. Edemir
Telefon: 0345/ 557 3170
Titel
A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
Indikation
Multiples Myelom
Art der Studie
Therapiestudie, interventionell, Phase 3
Therapielinie
Erstlinientherapie
Hauptprüfer am Zentrum (PI)
Dr. med. F. Brunner
Ansprechpartner
S. Edemir
Telefon: 0345/ 557 3170
Nicht-Interventionelle, nicht-medikamentöse Studien
Titel
Working Party Multiples Myelom - OSHO Myelomregister
Indikation
Multiples Myelom
Art der Studie
Prospektive Registerstudie, nicht-interventionell
Therapielinie
Erstlinientherapie und später
Hauptprüfer am Zentrum (PI)
Dr. med. F. Brunner
Ansprechpartner
S. Edemir
Telefon: 0345/ 557 3170
Mail: sabine.edemir@uk-halle.de